Boston Scientific CFO Dan Brennan to Retire, Jon Monson Named Successor

Boston Scientific Corporation, a leading medical device manufacturer, has announced significant changes in its executive leadership. Dan Brennan, the company's long-serving Chief Financial Officer (CFO), is set to retire after nearly three decades with the organization. This transition marks a pivotal moment for Boston Scientific as it navigates the evolving landscape of the medical technology industry.

Executive Transition and New Appointment

Dan Brennan, who has held the position of CFO since 2014, will step down from his role on June 30, 2025. Brennan's tenure at Boston Scientific spans almost 30 years, during which he has played a crucial role in shaping the company's financial strategy and performance.

Jon Monson, currently serving as the Senior Vice President for Investor Relations, has been named as Brennan's successor. Monson, a Boston Scientific veteran with over 25 years of experience within the company, will assume the CFO position effective June 30. In his new role, Monson will oversee key areas including global controllership and corporate business development.

Impact and Transition Period

CEO Mike Mahoney, who has worked alongside Brennan since taking the helm in 2012, praised the outgoing CFO's contributions, stating that Brennan had been "instrumental in transforming the trajectory of our financial performance." To ensure a smooth transition, Brennan will continue as a senior adviser through early October, working closely with Monson during this period.

The leadership change comes at a time when Boston Scientific faces external challenges, including the impact of tariffs imposed by the Trump administration. Despite these pressures, Mahoney expressed optimism about the company's outlook, describing the organization as "very bullish" on the year ahead.

Organizational Restructuring

As part of the ongoing organizational changes, Lauren Tengler, who previously served as the global controller for Boston Scientific's urology unit, will return to the investor relations team to succeed Monson. This move completes a series of strategic personnel shifts within the company's financial leadership structure.

The announcement of Brennan's retirement coincided with the release of Boston Scientific's quarterly earnings report, underscoring the company's commitment to transparent communication with investors and stakeholders during this transition period.